Nyxoah SA filings document the company's foreign-private-issuer reporting for its medical-technology business and the Genio system for obstructive sleep apnea. Form 6-K reports furnish quarterly and annual operating results, press releases, manufacturing-capacity updates, clinical and regulatory disclosures, and information incorporated by reference into registration statements on Form S-8 and Form F-3.
The filing record also covers capital-structure and governance matters, including ordinary-share offerings, underwriting agreements, shareholder voting matters, transparency-related ownership information, material-event reports, and exhibits that describe financing terms and public-company obligations.
Nyxoah SA adjusted its full-year revenue guidance to €33 to €35 million. The company expects U.S. growth to improve in Q4 compared with Q3 2026 and describes the U.S. sales ramp as more reflective of historical ramps for a new technology as physicians and centers build experience with Genio.
Nyxoah says it sees demand in growing numbers of active accounts and trained U.S. surgeons, and cites positive feedback on Genio. CEO Liam Kelly said the company remains confident in its ability to drive durable U.S. growth. Preliminary, unaudited third-quarter revenue results and cash, cash equivalents and financial assets are estimates subject to revision until Nyxoah reports full third-quarter results.
Nyxoah SA (NYXH) appointed Liam Kelly as chief executive officer, effective October 1, 2026, succeeding Olivier Taelman. The company said the appointment reflects its evolution into a U.S.-focused commercial organization following FDA approval and the U.S. launch of Genio. Kelly brings more than 25 years of leadership experience. He served as Teleflex’s president and chief executive officer from January 2018 to January 2026 and as its chairman from May 2020 to January 2026. Before Teleflex, he held senior management roles at Hill-Rom from 1999 to 2009. Kelly is also a director of Enovis Corporation.
Nyxoah SA (NYXH) announced a Chief Financial Officer transition. John Landry will step down as CFO effective October 2, 2026, and Loïc Moreau, currently President International and former CFO, will serve as Interim CFO from that date while a search for a permanent successor is conducted.
The company highlights Moreau’s prior CFO tenure from January 2022 to November 2024 and over 20 years of finance experience at firms including GSK, EY and PwC, emphasizing continuity in financial leadership. Nyxoah also reaffirmed its previously issued full-year 2026 financial guidance, signaling no change to its current financial outlook despite the leadership change.
CVI Investments, Inc. and Heights Capital Management, Inc. report beneficial ownership of 11,014,861 Ordinary Shares of Nyxoah SA, equal to 9.9% of the class. This position includes 828,803 Shares and additional Shares issuable upon conversion of convertible notes, subject to a 9.99% conversion cap on total beneficial ownership. Based on a company disclosure of 100,072,815 Shares outstanding as of June 30, 2026, Heights Capital, as investment manager to CVI, may exercise shared voting and dispositive power over these Shares, while both parties disclaim beneficial ownership beyond their pecuniary interest.
Nyxoah reported second-quarter and first-half 2026 results, with H1 2026 revenue of €14.0 million, up from €2.4 million a year earlier, as U.S. commercialization of its Genio system accelerated. U.S. revenue grew 22% sequentially in Q2 2026 over Q1 2026 and reached €9.5 million for the first half, alongside €4.6 million from international markets.
Despite higher gross profit of €8.2 million, heavy investment in growth led to a net loss of €48.9 million versus €43.0 million in H1 2025, while basic loss per share improved to €0.976 from €1.149 on a larger share base. Cash and financial assets totaled €97.8 million at June 30, 2026, supported by a Q2 equity raise and additional drawdown under the European Investment Bank term loan, providing liquidity for continued U.S. launch and clinical programs.
Nyxoah filed a Form 6-K combining shareholder transparency updates, capital structure data and strong preliminary second quarter 2026 results. U.S. launch momentum drove expected global net revenue of about €7.7 million, including €5.2 million from the U.S., both growing just over 20% sequentially. The company continued building its commercial footprint, training 55 new surgeons, activating 89 new high-volume accounts to reach 180, and entering Q3 with 427 patients submitted under prior authorization.
Nyxoah highlighted that CMS has proposed 2027 reimbursement increases for its Genio procedure, with hospital outpatient payment rising from $31,526 to $35,414 and ASC payment from $27,563 to $31,722. The company also secured $110 million in aggregate financing in Q2 and expects cash, cash equivalents and financial assets of about €97.8 million as of June 30, 2026. Separately, it reported new share count and potential dilution elements and disclosed updated ownership positions, including a 14.55% stake held by entities controlled by Orin Hirchman and a 1.95% stake for ResMed Inc.
ResMed Inc. filed an Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 1,943,828 ordinary shares of Nyxoah SA. The filing states this equals 1.95% of Nyxoah's 99,926,284 ordinary shares outstanding as of June 10, 2026. The filing is signed by Aaron Bloomer, Chief Financial Officer.
Nyxoah reported that it received $15 million (€13.8 million) from the second tranche of its loan facility with the European Investment Bank. Together with its recent underwritten equity offering, the company has raised about $110 million in new capital in June 2026.
The non-dilutive EIB debt is intended to fund the U.S. commercial launch of the Genio sleep apnea system, as well as research, development and manufacturing scale-up. Nyxoah also called an extraordinary shareholders’ meeting on July 9, 2026 to renew its authorized capital for up to an amount equal to its current share capital.
The filing further discloses updated ownership positions and threshold crossings for several significant holders, including Robert Taub, Pierre‑Edouard Stérin, Cochlear Limited, Gilde Healthcare and Bank of America Corporation, based on a total of 99,926,284 shares issued as of June 10, 2026.
NYXOAH Schedules beneficial ownership disclosure: AIGH entities and Orin Hirschman report 14,534,880 shares, representing 14.5% of Common Stock. The filing states sole voting and dispositive power over 14,534,880 shares. The filing is jointly made by AIGH Capital Management LLC, AIGH Investment Partners LLC and Mr. Orin Hirschman and is signed with dates shown.
Nyxoah SA filed a Form 6-K to furnish a press release updating investors on its total number of voting rights and shares. The update follows the issuance of 55,232,558 new shares in connection with a previously announced underwritten public offering in the United States.
The offering also included shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union. The press release attached as Exhibit 99.1 is furnished, not filed, under U.S. securities laws.